Firefly Neuroscience has identified a novel electrophysiological biomarker for post-traumatic stress disorder using its FDA-510(k)-cleared Evoke System, marking a breakthrough in objective PTSD assessment. The discovery comes following the company’s public-private partnership with the U.S. Department of War to support active-duty service members and veterans.
PTSD affects approximately 13 million Americans in any given year, with 11-20% of Operation Iraqi Freedom and Enduring Freedom veterans experiencing the condition annually. The total U.S. economic burden of PTSD is estimated at $232.2 billion, of which $42.7 billion is attributed directly to the military population.
The biomarker leverages Firefly’s deep learning architecture running on NVIDIA L40S GPU-accelerated infrastructure, enabling high-throughput analysis of multi-channel electroencephalogram (EEG) and Event-Related Potential (ERP) waveforms. The Evoke System’s dual-signal approach captures both resting-state hyperarousal patterns and abnormal cognitive ERP responses, making it particularly well-suited for PTSD diagnostics.
According to Firefly’s Chief Technology Officer Gil Issachar, the company applied its AI models to “a dataset that we believe to be unmatched in scale” and “identified a consistent and reproducible electrophysiological pattern distinguishing PTSD patients from healthy controls.” This discovery potentially opens commercial pathways across defense health, pharmaceutical clinical trials, and civilian clinical psychiatry. Firefly’s proprietary database now consists of over 200,000 EEG/ERP brain scans, making it what the company claims is the world’s largest known standardized repository.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/06/g52933330/fireflys-ai-driven-evoke-system-powers-discovery-of-novel-electrophysiological-biomarker-for-ptsd